Hemophilus Influenzae Type B Vaccine

G. Haroche, T. Lang, D. Rea, Ch Lafaix, Dan M. Granoff, Michael T. Osterholm, Trudy V. Murphy

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: We were very interested in the article by Peltola and colleagues reporting the effectiveness of immunization with a capsular polysaccharide Hemophilus influenzae type b (Hib) vaccine in preventing H. influenzae bacteremic infections in Finland (June 14 issue).1 As suggested by the authors, their recommendation that the Hib vaccine be given to all children at the age of 18 months may not necessarily be applicable in developing countries. We are conducting a study of the Hib vaccine, particularly its adjuvant effect, in children under 18 months of age in the Republic of Upper Volta (West Africa). In a.

Original languageEnglish (US)
Pages (from-to)53-54
Number of pages2
JournalNew England Journal of Medicine
Issue number1
StatePublished - Jan 3 1985


Dive into the research topics of 'Hemophilus Influenzae Type B Vaccine'. Together they form a unique fingerprint.

Cite this